Trial reportBMC anesthesiology2025
Butorphanol premedication improves postoperative lung function and analgesic outcomes in laparoscopic surgery: a randomized dose-response study.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeIn laparoscopic surgery, balancing effective analgesia with preservation of pulmonary function remains a clinical challenge. Butorphanol, a κ-opioid receptor agonist and partial µ-opioid receptor agonist, may offer advantages in respiratory protection and anti-inflammatory effects.
methodsThis prospective, randomized, double-blind, three-arm, single-center clinical trial was conducted at the Affiliated Hospital of Zunyi Medical University. Between June 2021 and December 2023, a total of 81 patients undergoing elective laparoscopic surgery were enrolled, including 28 in the control group, 27 in the low-dose butorphanol group (1 mg), and 26 in the high-dose butorphanol group (2 mg). All patients received an intramuscular injection of the assigned study drug 30 min before anesthesia induction. The primary outcome was intraoperative pulmonary gas exchange, including arterial partial pressure of oxygen (PaO
resultsCompared with the control group, butorphanol-particularly at 2 mg-significantly improved intraoperative pulmonary gas exchange. The high-dose group showed greater benefits in reducing airway pressures and anesthetic requirements, improving postoperative pulmonary function, suppressing inflammatory responses, and enhancing analgesic effects. During the 9-month follow-up, 70 patients completed all assessments, and the high-dose group consistently demonstrated superior recovery of pulmonary function, better quality of life, and lower levels of chronic pain.
conclusionPre-induction butorphanol enhances intraoperative pulmonary gas exchange and improves secondary outcomes, with 2 mg showing the most consistent benefits for ERAS protocols. CLINICAL
trial registrationThe study has been registered with the Chinese Clinical Trial Registry, registration number: ChiCTR2100047900. Registration date: June 27, 2021. Not retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.